An Arms Race against Leukemia Resistance: Clinically relevant drugs predominantly target the myeloid progenitor lineage, while monocyte or stem cell-like states can evade current AML treatments, akin to the lineage plasticity of leukemic stem cells (LSC). Read the Viewpoint article by Waclawiczek A., Leppä A.M., Renders S., Trumpp A. in pp. 475–478.

中文翻译：

---

发行信息

对抗白血病耐药性的军备竞赛：临床相关药物主要针对骨髓祖细胞谱系，而单核细胞或干细胞样状态可以逃避当前的 AML 治疗，类似于白血病干细胞 (LSC) 的谱系可塑性。请阅读 Waclawiczek A.、Leppä AM、Renders S.、Trump A. 撰写的观点文章，第 475-478 页。